EGFR and nasopharyngeal carcinoma: Individuals with nasopharyngeal cancer who underwent anti-EGFR in addition to conventional therapy were found to have better survival rates, but the difference was not statistically significant (HR = 1.18; 95%CI = 0.52–2.40; p = 0.7).